Presentation on theme: "A Randomized Multicenter Comparison of Radiofrequency Ablation and Antiarrhythmic Drug Therapy as First Line Treatment in 294 Patients with Paroxysmal."— Presentation transcript:
A Randomized Multicenter Comparison of Radiofrequency Ablation and Antiarrhythmic Drug Therapy as First Line Treatment in 294 Patients with Paroxysmal Atrial Fibrillation Jens Cosedis Nielsen, Professor, MD, DMSc, Aarhus, Denmark on behalf of the MANTRA-PAF investigators
MANTRA-PAF Investigators Arne Johannessen Gentofte University Hospital, CPH, Denmark Pekka Raatikainen Oulu University Hospital, Finland Gerhard HindricksLeipzig University Hospital, Germany Håkan Walfridsson University Hospital Linköping, Sweden Ole KongstadLund University Hospital, Sweden Steen PehrsonRigshospitalet, Copenhagen, Denmark Anders Englund University Hospital, Örebro, Sweden Juha HartikainenKuipio University Hospital, Finland Leif Spange MortensenUNI-C, Denmark (Datamanagement and statistics) Peter Steen Hansen Aarhus University Hospital, Skejby, Denmark (Chair, investigator committee) Jens Cosedis Nielsen Aarhus University Hospital, Skejby, Denmark (Coordinating investigator) Funding: The trial was supported by unrestricted grants from the Danish Heart Foundation and from Biosense Webster and Johnson&Johnson
Aim To compare radiofrequency ablation (RFA) with antiarrhythmic drug therapy (AAD) as first-line treatment in patients with paroxysmal atrial fibrillation (AF).
Methods Randomized controlled multicenter trial Antiarrhythmic drug therapy (Class IC or III) (AAD) versus pulmonary vein isolation (RFA) Power calculation: Assumed freedom from AF after 24 months in 75% (RFA) versus 60% (AAD) of the patients, α=0.05, 1-β=0.80, N=150 patients in each group Follow-up with 7-day Holter recordings after 3, 6, 12, 18 and 24 months Intention-to-treat analysis
Endpoints Primary endpoints: –Cumulative burden of AF –AF-burden at each 7-day Holter recording Secondary endpoints: –Freedom from any AF after 24 months –Freedom from symptomatic AF after 24 months –Burden of symptomatic AF after 3, 6, 12, 18, and 24 months –Atrial flutter –Quality of Life after 12 and 24 months –Serious adverse events
294 Patients Randomized 146 Assigned to RFA 140 Underwent RFA (96%) 148 Assigned to AAD 146 Started AAD (99%) After 24 months N=140; 223 RFA procedures (1.6±0.7) On AAD: N=13/138 (9%) (IC: 10, III: 3) Withdrawn N=5 Died N=3 666 7D Holter recordings After 24 months N=54; 87 RFA procedures (1.6±0.7) On AAD: N=100 /137 (73%) (IC: 86, III:14) Withdrawn N=7 Died N=4 665 7D Holter recordings 69 underwent repeated RFA Treatment with 1.24±0.48 AAD’s
Serious Adverse EventsRFAAAD Death34 Stroke10 Transient ischemic attack11 Pulmonary vein stenosis10 Tamponade30 Pericardial effusion, no puncture01 Suspected perforation at transseptal puncture10 Atrial flutter, 1:1 AV conduction02 Atrial flutter or atrial tachycardia33 Cardiac incompensation02 Perimyocarditis10 Bradycardia with need of pacemaker01 Ventricular tachycardia and need for ICD10 Hematoma related to anticoagulation10 Retroperitoneal bleeding, coiling of small artery10 Chest discomfort10 Discomfort probably due to medication02 Cancer64 Other (Rotator cuff rupture, Arthroscopy, Gallbladder surgery)12 Total2522
Conclusions At 24 months AF-burden and occurrence of any and symptomatic AF were significantly lower in the RFA group than in the AAD group. No significant difference was observed in the cumulative burden of AF between AAD and RFA. QOL (PCS) better in the RFA group after 12 and 24 months. These data support RFA as a first-line treatment in patients with paroxysmal AF.
Discussion Selected patient population. Not an argument for offering all patients with paroxysmal AF radiofrequency ablation! Both strategies should be discussed with the patients and considered by patients and physicians when rhythm control for symptomatic paroxysmal AF is indicated. The results of the MANTRA-PAF trial support the idea of early ablation for AF to avoid progression of AF on the long term.